Because hPAR4Thr/Thr mice exhibited persistent platelet activation despite in vivo administration of a P2Y12 antagonist (Figure 6, F–H, and Supplemental Figure 21), we investigated whether adding aspirin to the regimen (DAPT, a standard approach in patients) would improve stroke outcomes. The gene discussed is P2RY12; the disease is Stroke.